Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older

Hassan N. Ibrahim, Areef Ishani, Haifeng Guo, David T. Gilbertson

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background. Erythropoiesis stimulating agents (ESA) have alleviated the need for blood transfusions in dialysis patients. Their impact on transfusion frequency in elderly chronic kidney disease (CKD) patients aged 65 years and older with non-dialysis-dependent CKD has not been studied.Methods. We conducted a retrospective cohort study of Medicare beneficiaries with CKD, point prevalent as of 1 January of each calendar year 1992-2004 (n = 301000), and a concurrent group of beneficiaries without CKD (n = 15772039). During the entry year, we used administrative claim data to assemble a comorbidity profile for each participant. Transfusion event rates, ESA use and parenteral iron use were of primary interest.Results. CKD patients were at least four times more likely than non-CKD patients to receive transfusions. Transfusion rates adjusted for case mix fell from 194.2 transfusions per 1000 patient-years in 1992 to 112.2 in 2004. The decline in transfusions was highest for anaemic CKD patients receiving ESAs, which were given to 0.8 of CKD patients in 1992 and to 7.5 in 2004.Conclusions. Transfusion use in non-dialysis-dependent CKD patients has decreased considerably but continues to be common. ESA use and possibly changed attitudes towards transfusion use explain most of the reduction noted.

Original languageEnglish (US)
Pages (from-to)3138-3143
Number of pages6
JournalNephrology Dialysis Transplantation
Issue number10
StatePublished - Oct 2009

Bibliographical note

Funding Information:
1Chronic Disease Research Group, Minneapolis Medical Research Foundation, 2Department of Medicine, University of Minnesota and 3Section of Nephrology, Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA

Funding Information:
Conflicts of interest statement. This study was supported by a research contract from Amgen Inc., Thousand Oaks, CA, USA. The contract provides for the authors to have final determination of the content of this manuscript. D.T.G. has received consulting fees from Amgen. H.N.I. and A.I. consult for, and H.G. is employed by, the Chronic Disease Research Group.


  • Chronic kidney disease
  • Erythropoiesis stimulating agents
  • Transfusions


Dive into the research topics of 'Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older'. Together they form a unique fingerprint.

Cite this